Evren Alici group

Gene therapy is one of the most exciting developments in medical research. Comprehending the full potential of this new therapeutic approach will have a significant impact on the treatment of many acquired and inherited disorders.

In recognition of this potential, the Gene Therapy Program at our institution was initiated and the first approvals from the Medical Products Agency and the Ethical committee at Huddinge Hospital to treat patients were granted in 1992.

The first patient received gene modified cells in December 1995

The first study tried to reveal the mechanism of relapse after autologous stem cell transplantation for multiple myeloma. The first patient received gene modified cells in December 1995 making this study the first gene therapy clinical trial in Sweden.

The program includes a number of targeted clinical and basic research projects.

Clinical research projects have been developed against cancer. Basic research programs have been developed in suicide gene technologies, stem cell and lymphocyte biology, immunotherapy, gene expression and cytogenetics.

Today, we have international leading competence in clinical grade, current good manufacturing practice (GMP) compatible cell and gene therapy applications.


Evren AliciGroup leader, Assistant Professor of Hematology

Dr. Evren Alici is an Assistant Professor of Hematology at Karolinska Institutet, Department of Medicine, Stockholm, Sweden. He received his MD and did his residency at the Ege University. He received his Ph.D. in 2006 at Karolinska Institutet. His main research interest is natural killer cells, multiple myeloma, lentiviral and retroviral gene transfer, stem cell transplantation and immunology. He is a member of several international and national committees, advisory boards and scientific meetings. He has mentored many trainees, 3 PhD. students and 2 post docs.

Birgitta StellanBiomedical research analyst

Educated and highly experienced in clinical cytogenetics as well as GMP work. Developed a close system for NK cell expansion. Specializes in primary cell culture under GMP conditions. Attended courses in flow cytometry , scientific methodology and hematological diseases.

Mari Gilljam, Biomedical research analyst

Educated and highly experienced in GMP work. Developed a closed system for expansion of NK cells. Specializes in multi-color flow cytometry and primary cell culture under GMP conditions.

Tolga Sutlu, Post-doctoral researcher

Received B.Sc. degree in Biological Sciences and Bioengineering from Sabanci University Istanbul in 2004. Worked as a Molecular Biologist in Acibadem Genetic Diagnosis and Cell Therapy Center Istanbul for a year before moving to Sweden to attend Stockholm Research School in Molecular Life Sciences . Received his Ph.D. in Medical Sciences from the Karolinska Institutet in 2012. Specializes in molecular biology, primary cell culture, multi-color flow cytometry and experimental cell and gene therapy.

Adil Doganay DuruPost-doctoral researcher

Received his PhD in Medical Sciences at the Karolinska Institutet in 2012. After a B.Sc. in Biological Sciences and Bioengineering from Sabanci University Istanbul in 2004, he worked as a research assistant on high-throughput analysis of gene expression in cancer cells using SAGE and microarray at Bogazici University Istanbul until 2007. Now he specializes in molecular biology, structural biology, primary cell culture, multi-color flow cytometry and experimental murine models.

Michael ChrobokPhD Student

Received B.Sc. degree in Biochemistry from Leibniz University Hannover and M.Sc in Molecular Life Sciences from University of Hamburg. After finishing his master project at the Heinrich-Pette Institute in Hamburg he started recently his PhD studies in Evren Alici´s lab at the Karolinska Institutet.

Selected publications

In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmidéne et al.
Sutlu T, Alici E, Gahrton G, Nahi H
Med. Oncol. 2013 ;30(2):569

A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.
Uttervall K, Admasie J, Alici E, Lund J, Liwing J, Aschan J, et al
Acta Haematol. 2013 ;130(1):7-15 

Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy.
Sutlu T, Nyström S, Gilljam M, Stellan B, Applequist S, Alici E
Hum. Gene Ther. 2012 Oct;23(10):1090-100

Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study.
Jungebluth P, Alici E, Baiguera S, Le Blanc K, Blomberg P, Bozóky B, et al
Lancet 2011 Dec;378(9808):1997-2004

Ex vivo expansion of natural killer cells: a question of function.
Sutlu T, Alici E
Cytotherapy 2011 Jul;13(6):767-8

Clinical impact of chromosomal aberrations in multiple myeloma.
Nahi H, Sutlu T, Jansson M, Alici E, Gahrton G
J. Intern. Med. 2011 Feb;269(2):137-47

IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers.
Alici E
Curr. Opin. Mol. Ther. 2010 Dec;12(6):724-33

GMP facilities for manufacturing of advanced therapy medicinal products for clinical trials: an overview for clinical researchers.
Alici E, Blomberg P
Curr Gene Ther 2010 Dec;10(6):508-15

Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.
Sutlu T, Stellan B, Gilljam M, Quezada H, Nahi H, Gahrton G, et al
Cytotherapy 2010 Dec;12(8):1044-55

Suicide gene therapy for graft-versus-host disease.
Georgoudaki A, Sutlu T, Alici E
Immunotherapy 2010 Jul;2(4):521-37

HematologyRegenerative Medicine